guest ::
| Home > Publications Database > Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives. > print |
| Home > Publications Database > Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives. > print |
| 001 | 163947 | ||
| 005 | 20240313115344.0 | ||
| 024 | 7 | _ | |a 10.1089/nat.2021.0039 |2 doi |
| 024 | 7 | _ | |a pmid:34591693 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC9058873 |2 pmc |
| 024 | 7 | _ | |a 1050-5261 |2 ISSN |
| 024 | 7 | _ | |a 1050-8526 |2 ISSN |
| 024 | 7 | _ | |a 1087-2906 |2 ISSN |
| 024 | 7 | _ | |a 1545-4576 |2 ISSN |
| 024 | 7 | _ | |a 1557-8526 |2 ISSN |
| 024 | 7 | _ | |a 2159-3337 |2 ISSN |
| 024 | 7 | _ | |a 2159-3345 |2 ISSN |
| 024 | 7 | _ | |a 2168-6599 |2 ISSN |
| 024 | 7 | _ | |a 2690-7577 |2 ISSN |
| 024 | 7 | _ | |a altmetric:114317477 |2 altmetric |
| 037 | _ | _ | |a DZNE-2022-00621 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Synofzik, Matthis |0 P:(DE-2719)2811275 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives. |
| 260 | _ | _ | |a New Rochelle, NY |c 2022 |b Liebert |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1655197538_923 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a (CC BY) |
| 520 | _ | _ | |a Antisense oligonucleotide (ASO) therapies present a promising disease-modifying treatment approach for rare neurological diseases (RNDs). However, the current focus is on 'more common' RNDs, leaving a large share of RND patients still without prospect of disease-modifying treatments. In response to this gap, n-of-1 ASO treatment approaches are targeting ultrarare or even private variants. While highly attractive, this emerging, academia-driven field of ultimately individualized precision medicine is in need of systematic guidance and standards, which will allow global scaling of this approach. We provide here genetic, regulatory, and ethical perspectives for preparing n-of-1 ASO treatments and research programs, with a specific focus on the European context. By example of splice modulating ASOs, we outline genetic criteria for variant prioritization, chart the regulatory field of n-of-1 ASO treatment development in Europe, and propose an ethically informed classification for n-of-1 ASO treatment strategies and level of outcome assessments. To accommodate the ethical requirements of both individual patient benefit and knowledge gain, we propose a stronger integration of patient care and clinical research when developing novel n-of-1 ASO treatments: each single trial of therapy should inherently be driven to generate generalizable knowledge, be registered in a ASO treatment registry, and include assessment of generic outcomes, which allow aggregated analysis across n-of-1 trials of therapy. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a antisense oligonucleotides |2 Other |
| 650 | _ | 7 | |a ethics |2 Other |
| 650 | _ | 7 | |a n-of-1 |2 Other |
| 650 | _ | 7 | |a policy |2 Other |
| 650 | _ | 7 | |a rare diseases |2 Other |
| 650 | _ | 7 | |a rare neurological diseases |2 Other |
| 650 | _ | 7 | |a regulatory |2 Other |
| 650 | _ | 7 | |a Oligonucleotides |2 NLM Chemicals |
| 650 | _ | 7 | |a Oligonucleotides, Antisense |2 NLM Chemicals |
| 650 | _ | 2 | |a Europe |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Oligonucleotides |2 MeSH |
| 650 | _ | 2 | |a Oligonucleotides, Antisense: genetics |2 MeSH |
| 650 | _ | 2 | |a Oligonucleotides, Antisense: therapeutic use |2 MeSH |
| 700 | 1 | _ | |a van Roon-Mom, Willeke M C |b 1 |
| 700 | 1 | _ | |a Marckmann, Georg |b 2 |
| 700 | 1 | _ | |a van Duyvenvoorde, Hermine A |b 3 |
| 700 | 1 | _ | |a Graessner, Holm |b 4 |
| 700 | 1 | _ | |a Schüle, Rebecca |0 P:(DE-2719)2812018 |b 5 |u dzne |
| 700 | 1 | _ | |a Aartsma-Rus, Annemieke |0 0000-0003-1565-654X |b 6 |
| 773 | _ | _ | |a 10.1089/nat.2021.0039 |g Vol. 32, no. 2, p. 83 - 94 |0 PERI:(DE-600)2639888-6 |n 2 |p 83 - 94 |t Nucleic acid therapeutics |v 32 |y 2022 |x 1050-5261 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/163947/files/DZNE-2022-00621.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/163947/files/DZNE-2022-00621.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:163947 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)2811275 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2812018 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-29 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NUCLEIC ACID THER : 2021 |d 2022-11-29 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-29 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-29 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-29 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-29 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-29 |
| 920 | 1 | _ | |0 I:(DE-2719)1210000 |k AG Gasser 1 |l Parkinson Genetics |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)5000024 |k AG Maetzler |l Functional Neurogeriatrics |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1210000 |
| 980 | _ | _ | |a I:(DE-2719)5000024 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|